irone sucrose

PreclinicalSmall molecule

KKaohsiung Medical University Chung-Ho Memorial Hospital

irone sucrose is one of 7 small molecule programs targeting End-Stage Renal Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

End-Stage Renal DiseaseUnknown status

End-Stage Renal DiseasePreclinical

Unknown status

Competition

Competitive Landscape

7 competitors in End-Stage Renal Disease

#DrugCompanyPhaseTrials

Prograf

VVeloxis Pharmaceuticals

Approved

2 2

Wellbutrin

GSK

Preclinical

1 3

Apabetalone

RResverlogix Corp

Phase 2

1 4

Ribupatide

KKailera

Phase 1

1 5

Sevelamer Hydrochloride

Sanofi

Preclinical

1 6

Equine Anti-Thymocyte Globulin

NNational Cancer Institute (NCI)

Preclinical

1 7

irone sucrose

KKaohsiung Medical University Chung-Ho Memorial Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

End-Stage Renal Disease1 trial

Iron Therapy in Patients With End-Stage Renal Disease

Unknown status·KKaohsiung Medical University Chung-Ho Memorial Hospital·N/A·NCT04491916·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for irone sucrose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — irone sucrose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for irone sucrose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kaohsiung Medical University Chung-Ho Memorial Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: KKaohsiung Medical University Chung-Ho Memorial Hospital

irone sucrose

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

End-Stage Renal Disease1 trial

References

Drug Info

Quick Facts

Related News